Disease Modifying Therapies in Multiple Sclerosis: Strategies to Optimize Clinical Management

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Biogen, Celgene Corporation, Novartis Pharmaceuticals Corporation and Sanofi Genzyme

Description:
Multiple Sclerosis (MS) is a chronic progressive disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. Currently treatment is focused on disease-modifying agents, which helps lessen the frequency and severity of relapses, reduce lesions in the brain, and help slow or stop disability. At present time, only one-third to one-half of the 400,000 individuals in the US have received treatment with these disease-modifying agents. While this is not a cure for multiple sclerosis, disease-modifying treatments have greatly improved the quality of life for patients with MS. Effective and timely treatment of relapsing MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, clinicians are being challenged to quickly diagnose MS and its corresponding symptoms, and provide the correct treatment options that are available to patients. This presentation will update care providers on the current and emerging treatments and strategies in the management of relapsing MS.

Upon completion of this activity, participants will be able to:

• Compare and contrast the safety, efficacy, and attributes of current and emerging multiple sclerosis (MS) therapies

• Analyze evidence-based data for the rationale of sequencing, switching, and/or escalating MS therapeutics

• Examine the role of oral therapies in the management of patients with MS

• Explore the available methods to predict and monitor disease worsening in patients with MS

• Review available data on established and investigational S1P modulators and where they fit in the treatment paradigm

• Discuss managed care considerations of current and emerging therapies by exploring where these agents fit into the current relapsing MS management paradigm
   

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Biogen, Celgene Corporation, Novartis Pharmaceuticals Corporation and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue